Drugs / A1811
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07844291 | Nov 2026 → Dec 2031 expected | breast cancer | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞ADC创新药瑞康曲妥珠单抗单药或联合帕妥珠单抗一线治疗HER2阳性晚期乳腺癌III期临床研究达到主要终点 hengrui.com ↗
方案预设的期中分析结果表明，与对照组相比，瑞康曲妥珠单抗联合或不联合帕妥珠单抗均可显著降低患者疾病进展/死亡风险 1 。 |
| 2026-08-26 | Jiangsu HengRui Medicine Co., Ltd. | Results 高表达人群ORR达91.7%！恒瑞ADC创新药瑞康曲妥珠单抗治疗晚期唾液腺癌HER2分层II期研究荣登JCO hengrui.com ↗
HER2高表达队列（n=24）中位随访21.9个月，确认ORR高达91.7%（95% CI：73.0-99.0），含4例完全缓解（CR）、18例部分缓解（PR），疾病控制率（DCR）为95.8%；中位DoR、PFS、OS均未达到，中位TTR仅为1.7个月。 |
| 2026-07-02 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer glenmarkpharma.com ↗
India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). |
| 2026-04-10 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞HER2 ADC创新药瑞康曲妥珠单抗晚期实体瘤全球I期临床最终分析登上《自然》子刊STTT hengrui.com ↗ |
| 2026-03-23 | Jiangsu HengRui Medicine Co., Ltd. | Results 荣登JCO！恒瑞HER2 ADC创新药瑞康曲妥珠单抗治疗胃/胃食管结合部腺癌和结直肠癌I期结果发布 hengrui.com ↗
研究结果初步展示了瑞康曲妥珠单抗在HER2表达的GC/GEJ和CRC患者中具有良好的抗肿瘤活性和安全性 [1] 。 |
| 2025-10-23 | Jiangsu HengRui Medicine Co., Ltd. | Results 2025 ESMO口头报告︱达到主要终点！恒瑞ADC创新药瑞康曲妥珠单抗有望为HER2阳性晚期乳腺癌患者带来新希望 hengrui.com ↗
BICR评估的中位PFS方面，瑞康曲妥珠单抗组达到30.6个月（95%CI：16.8-NR），吡咯替尼联合卡培他滨组为8.3个月（95%CI：6.9-11.0）。 |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞ADC创新药瑞康曲妥珠单抗单药或联合帕妥珠单抗一线治疗HER2阳性晚期乳腺癌III期临床研究达到主要终点 hengrui.com ↗ |
| 2026-08-26 | Jiangsu HengRui Medicine Co., Ltd. | 高表达人群ORR达91.7%！恒瑞ADC创新药瑞康曲妥珠单抗治疗晚期唾液腺癌HER2分层II期研究荣登JCO hengrui.com ↗ |
| 2026-07-02 | Glenmark Pharmaceuticals Ltd. India | Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer glenmarkpharma.com ↗ |
| 2026-04-10 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞HER2 ADC创新药瑞康曲妥珠单抗晚期实体瘤全球I期临床最终分析登上《自然》子刊STTT hengrui.com ↗ |
| 2026-03-23 | Jiangsu HengRui Medicine Co., Ltd. | 荣登JCO！恒瑞HER2 ADC创新药瑞康曲妥珠单抗治疗胃/胃食管结合部腺癌和结直肠癌I期结果发布 hengrui.com ↗ |
| 2025-10-23 | Jiangsu HengRui Medicine Co., Ltd. | 2025 ESMO口头报告︱达到主要终点！恒瑞ADC创新药瑞康曲妥珠单抗有望为HER2阳性晚期乳腺癌患者带来新希望 hengrui.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A1811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07844291 ↗ |